Case Reports in Medicine

Case Reports in Medicine / 2015 / Article

Case Report | Open Access

Volume 2015 |Article ID 567543 | 10 pages | https://doi.org/10.1155/2015/567543

Mandibular Brown Tumor of Secondary Hyperparathyroidism Requiring Extensive Resection: A Forgotten Entity in the Developed World?

Academic Editor: W. Zidek
Received07 Jun 2015
Accepted05 Aug 2015
Published19 Aug 2015

Abstract

Brown tumor of hyperparathyroidism (BTHPT) is rare in the United States and not frequently seen in clinical practice. This is likely because early diagnosis and prompt treatment of this disease process prevent the progression and development of BTHPT. Conversely, BTHPT is more common in underdeveloped countries where fewer patients have access to health care and hyperparathyroidism (HPT) goes untreated. It has been reported that the incidence of BTHPT in underdeveloped countries can be as high as 58 to 69 percent in patients with primary HPT. We present a case report of a patient in the United States with a large mandibular BTHPT requiring an extensive resection in the setting of secondary HPT. Despite being rare in this country, it is important for nephrologists, primary care physicians, and oral health care providers to be able to recognize this entity, so that intervention may be rendered early.

1. Introduction

In a healthy individual, the parathyroid glands and kidneys play an important role in the homeostasis and regulation of serum calcium (Ca) and phosphorus (P) levels. Parathyroid hormone (PTH) is released in response to decreased serum Ca and functions to increase this by causing an efflux of Ca from the bony skeleton and increased reabsorption by the kidneys. PTH also leads to increased release of vitamin D from the kidneys, which in turn causes increased Ca absorption from the gastrointestinal tract. Conversely, PTH leads to decreased P levels due to increased excretion by the kidneys [1].

Hyperparathyroidism (HPT) is a disorder characterized by an excessive amount of parathyroid hormone secretion by the parathyroid glands. Depending on the cause of this PTH production, HPT can be characterized into primary, secondary, and tertiary forms [2, 3].

Primary HPT occurs when one or more parathyroid glands secrete an excessive amount of PTH, as in the case of a parathyroid adenoma; secondary HPT results when increased secretion of PTH is a response to lowered ionized calcium, typically as a result of renal disease [4]. In tertiary HPT, secretion of PTH occurs as a result of long-standing chronic renal disease eventually leading to overactive parathyroid glands that become independent of the underlying disease. Hence, tertiary HPT is not corrected when patients receive a renal transplant that corrects the underlying renal etiology [5].

When any of these forms of HPT are not well controlled, BTHPT may result. These nonneoplastic lesions present late in untreated disease and are more commonly seen in underdeveloped countries due to the lack of access to care; they are infrequently seen in developed countries [6]. These lesions appear identical to central reparative giant cell granulomas histologically and result because of the abnormal calcium homeostasis in HPT [2]. Treatment for these lesions is often directed at the management of the underlying HPT, which frequently results in regression and resolution of these lesions without surgical intervention. However, surgical treatment may be required in refractory cases or in large symptomatic lesions [7].

2. Case Report

A 43-year-old African American male presented to the Division of Oral Oncology at the University of Mississippi Cancer Institute with the chief complaint of swelling in his right mandible that had been present for approximately one year (Figure 1). Oral exam revealed a 5.0 × 7.0 cm bulbous mass arising from the mandible and obliterating the right side of the oral cavity. The mass was ulcerated due to occluding with the opposing dentition. The patient denied pain but reported difficulty in eating. A computed tomography (CT) scan (Figures 2(a) and 2(b)) showed an expansile osseous lesion, involving the entire height of the mandible and extending from the right first premolar all the way posteriorly to involve the ramus and coronoid process. This lesion caused severe bony destruction of the mandible, eroding through both buccal and lingual cortices and filling the right half of the oral cavity.

The patient’s past medical history was significant for end stage renal disease (ESRD). He was on hemodialysis and was followed by a nephrologist. He had secondary HPT which was not well controlled, with a PTH level of 1,818 pg/mL at the time of presentation (normal range (NR) 11 to 77 pg/mL). This was thought to be likely due to noncompliance with his medications and due to refractory disease. The remainder of his labs was as follows: Ca 8.4 (NR 9–10.5 mg/dL), P 5.3 (NR 3.0–4.5 mg/dL), blood urea nitroge 28 (NR 8–20 mg/dL), and creatinine 7.17 (NR 0.7–1.3 mg/dL).

Based on the past medical history, this lesion was highly suspicious for BTHPT. However, given the rarity of brown tumors and the clinical appearance and size of this lesion, other osseous and odontogenic tumors could not be excluded. An incisional biopsy was performed and histologic examination confirmed the diagnosis of BTHPT.

Microscopically, the lesion was composed of a highly cellular proliferation of bland spindle-shaped fibroblastic cells with numerous multinucleated giant cells (Figure 3) and spicules of woven bone. The osteoclastic giant cells were scattered throughout the cellular stroma and surrounded small spicules of bone (Figure 4). Small blood vessels, extravasated red blood cells, and focal deposits of hemosiderin were seen throughout the lesion, especially toward the periphery. The native bone showed evidence of intense bone resorption secondary to osteoclast hyperactivity and marrow fibrosis, consistent with secondary hyperparathyroidism (Figure 5). The histologic appearance of the lesion was akin to central giant cell reparative granuloma.

A discussion was held with the patient and treating nephrologist. Given the extent of the tumor and the uncontrolled underlying disease, it was decided that surgical intervention was the best option. Segmental resection with minimal margins was performed because marginal resection or enucleation procedures were deemed not feasible due to the limited amount of bone. This was done via a transcervical lip splitting approach due to limited access from the extensive size of the tumor (Figures 68 and supplemental video in Supplementary Material available online at http://dx.doi.org/10.1155/2015/567543). A microvascular free tissue transfer was not performed at that time because the treating nephrologist did not feel the patient could tolerate a lengthy surgery. Virtual surgical planning was utilized to help plan the mandibular resection as well as the reconstruction bar placement (Figure 9). Postoperatively, the patient’s hospital course was uneventful. He was followed up by the inpatient nephrology team and continued to receive dialysis while he remained in the hospital.

The patient was followed up for several weeks after surgery, and initial healing was within normal limits. Unfortunately, the patient was noncompliant with long term follow-up despite very extensive efforts to get him rescheduled. This noncompliance may have potentially contributed to the initial presentation of the tumor.

3. Discussion

BTHPT is rare in the United States and not frequently seen in clinical practice. Conversely, BTHPT is more common in underdeveloped countries where fewer patients have access to health care and HPT goes untreated. A review of the literature over the last 10 years identified a total of 87 patients in 57 reports with BTHPT of the facial region. Analysis of this data is provided in Table 1. Only 5 of those cases occurred in the United States [812]. Of those, four had primary HPT, and one had secondary disease, as our patient did. The highest number of BTHPTs was reported from Mexico, India, and Brazil, respectively. Of the total 87 patients identified with BTHPT, 64 were females and 23 were males (2.8 : 1). The mean age was 42 years (11 to 83). Two-thirds (66.7%) were comprised of primary HPT, while secondary HPT made up 27.6% of cases; tertiary HPT made the remaining 5.7%. With regard to site of occurrence, 48% occurred in the mandible, 38% occurred in the maxilla, and 14% involved both jaws.


AuthorYearCountryPatient agePatient genderTumor locationType of HPTTreatmentLesion size (CM)

Chowdhury et al.
[33]
2013Brazil20FMAX & MAND1° HPTPTE3 3

Pawlak et al. [34]2013Poland32FMAND1° HPTPTE + EX BTna
57FMAND1° HPTPTE + EX BTna
42FMAX 1° HPTPTE + EX BTna
66FMAX & MAND1° HPTPTE + EX BTna
32MMAX & MAND1° HPTPTE + EX BTna

de Ávila et al. [35]2012Brazil21MMAND3° HPTPTE + CUR BTna

Pace and Crosher
[3]
2010UK27FMAX & MAND2° HPTMED MGMTna

Angadi et al. [36]2010India38MMAND1° HPTPTE + EX BT

Benhammou et al. [37]2009France23FMAX & MAND1° HPTPTEna

Selvi et al. [38]2009Turkey19MMAX & MAND3° HPTMED MGMT

Karabekmez et al.
[39]
2008Turkey11MMAX & MAND2° HPTna

Tarrass et al. [40]2008Morocco18MMAND2° HPTPTE

Jebasingh et al. [41]2008India68MMAX1° HPTPTEna

Dinkar et al. [42]2007India36FMAND1° HPTnana

Desigan et al. [43]2007UK27FMAND1° HPTPTE

Pinto et al. [31]2006Brazil12FMAND3° HPTICCTna

Prado et al. [27]2006Brazil45FMAND2° HPTPTE

Triantafillidou
et al. [7]
2006Greece76FMAX & MAND1° HPTPTEna
71MMAND1° HPTPTEna
21FMAND2° HPTCUR BT + MED MGMTna
70FMAND2° HPTCUR BT + MED MGMTna
68FMAND2° HPTCUR BT + MED MGMTna

Grulois et al. [44]2005Belgium57FMAND1° HPTnana

Fernández-Sanromán et al.
[45]
2005Spain16FMAND1° HPTPTE + CUR BTna

Jović et al. [46]2004Serbia25MMAX2° HPTPTE + EX BTna

Sumer et al.
[32]
2004Saudi Arabia41FMAND2° HPTPTE

Emin et al. [47]2004Turkey62FMAND1° HPTPTE + EX BT

Suarez-Cunqueiro et al. [18]2004Germany26MMAND1° HPTPTEna

Gangidi et al. [19]2012UK83FMAND1° HPTPTEna

Placed et al. [48]2010Spain33FMAX2° HPTnana

Pinto et al. [22]2010Brazil37FMAX2° HPTPTEna

Pérez-Guillermo
et al. [49]
2006Spain61MMAX2° HPTPTE + EX BT

Daniels [16]2004Saudi Arabia25FMAX1° HPTPTE + CUR BTna

Reséndiz-Colosia
et al. [20]
2008Mexico51FMAX1° HPTPTE5
27FMAX1° HPTPTE4
62MMAX1° HPTPTE4
77FMAX1° HPTPTE3
48MMAX1° HPTPTE4
57FMAX1° HPTPTE4
64FMAX1° HPTPTE4
28FMAND1° HPTPTE3
55FMAND1° HPTPTE3
57FMAND1° HPTPTE4
41FMAND1° HPTPTE3
45FMAND1° HPTPTE2
68FMAND1° HPTPTE2
45FMAND1° HPTPTE5
41FMAND1° HPTPTE2
67FMAND1° HPTPTE2
53FMAND1° HPTPTE4
35FMAND1° HPTPTE2
42FMAND1° HPTPTE3
54FMAND1° HPTPTE3
36FMAND1° HPTPTE5
70FMAND1° HPTPTE4

Praveen and Thriveni [50]2012India21FMAX & MAND2° HPTRECON BAR; ;

Arunkumar et al. [51]2012India12FMAND2° HPTEX BT + MED MGMTna

Soundarya et al.
[52]
2011India60MMAX1° HPTEX BT na

Jakubowski et al. [8]2011USA49MMAND2° HPTna

Sutbeyaz et al. [53]2009Turkey53MMAX & MAND1° HPTPTE;

Proimos et al. [15]2009Greece42FMAX1° HPTEX BT2

Rafizadeh et al. [10]2013USA43MMAX1° HPTnana

Wilson et al. [12]2013USA26FMAX1° HPTICTna

Mantar et al. [54]2012Turkey23MMAX1° HPTPTEna

Nabi et al. [55]2010Saudi Arabia24FMAX2° HPTPTEna

Di Daniele et al. [21]2009Italy40FMAX2° HPTPTE4

Leal et al. [24]2006Brazil31FMAX2° HPTPTE + EX BTna

Oh et al. [9]2006USA53FMAX1° HPTPTE + EX BT0.8

Pechalova and Poriazova [17]2013Bulgaria19MMAND2° HPTEX BT5
49FMAX2° HPTEX BTna

Sia et al. [56]2012China29FMAX1° HPTPTE + EX BT

Bahrami et al. [57]2012Iran38FMAX1° HPTPTE + EX BTna

Walsh et al. [11]2005USA13FMAX & MAND1° HPTPTE + EX BTna

Di Fede et al. [58]2013Italy71MMAND1° HPTnana

Alhusban and Baqain [59]2011Jordan45FMAND1° HPTPTE + EX BTna

Pahlavan and Severin [60]2006Germany21MMAND1° HPTPTEna

Altay et al. [61]2013Turkey59MMAX3° HPTPTE

Artul et al. [62]2013Israel46FMAX2° HPTMED MGMT2.2

Guldfred et al. [63]2012Denmark34FMAX1° HPTEX BTna

Nair et al. [25]2011India35FMAND2° HPTMED MGMT

Magalhães et al. [64]2010Brazil58FMAX & MAND3° HPTPTEna

Pati et al. [65]2014India34MMAX1° HPTna

Mori et al. [66]2013Japan52FMAX1° HPTPTEna

Benjelloun et al. [67]2007Morocco17FMAX2° HPTPTEna

Thomas et al. [68]2011India27FMAND2° HPTEX BT + MED MGMT4 × 6

Guerrouani et al. [69]2013Morocco41FMAX1° HPTPTEna

Mandible = MAND, maxilla = MAX, hyperparathyroidism = HPT, not available = na, male = M, female = F, parathyroidectomy = PTE, excision of brown tumor = EX BT, curettage of brown tumor = CUR BT, medical management = MED MGMT, intralesional corticosteroid and calcitonin therapy = ICCT, mandibulectomy and reconstruction bar placement = RECON BAR, and intralesional corticosteroid therapy = ICT.

BTHPT occurs late in the setting of HPT and is considered as a sign of poorly controlled disease. The prevalence of BTHPT is low, with a reported frequency of 3% in primary HPT and 2% in secondary HPT [13]. Brown tumors occur due to abnormal calcium homeostasis in the setting of uncontrolled parathyroid disease, resulting in significant bone demineralization. Long-standing brown tumors, also known as osteitis fibrosa cystica, often undergo central degeneration and exhibit fibrous marrow replacement, causing a cyst-like radiographic appearance [13]. Histologically, these lesions are identical to central reparative giant cell granulomas, consisting of a spindle cell stroma and numerous multinucleated osteoclast-like giant cells. This lesion is referred to as “brown tumor” due to the reddish brown color of the tissue specimen, secondary to extravasated red blood cells and hemosiderin deposition [7, 14]. Because it is difficult to distinguish histologically between BTHPT and other giant cell lesions, the clinical diagnosis is made based on serum chemistries and the presence or absence of HPT [15].

Primary HPT is the third most common endocrine disorder. The prevalence is reported at 1 per 1000 in the United States [5]. The most common cause of primary HPT is single gland adenoma, which represents around 90% of cases [2, 5, 7, 14]. In most cases, primary HPT is diagnosed incidentally by hypercalcemia and patients are often asymptomatic [16]. However, less frequently, patients with primary HPT will display signs and symptoms of the disease. Symptoms are often related to chronic hypercalcemia and can include nephrolithiasis, muscle weakness, osteoporosis, and psychiatric symptoms [5, 14]. Secondary HPT can be caused by either a vitamin D deficiency or chronic kidney disease, both of which lead to hypocalcemia and thus stimulation of the parathyroid glands. Unlike primary HPT, secondary HPT is typically associated with serum hypocalcemia and hyperphosphatemia [5, 7]. Patients with chronic kidney disease display renal osteodystrophy, which can result in bone loss, bone pain, and fractures [17].

The treatment of BTHPT varies from case to case. However, the treatment of choice related to primary HPT is most commonly to remove the offending parathyroid gland [4]. Many authors report that, after parathyroidectomy, tumor regression and healing will occur [1822]. The most common approach to identifying the offending parathyroid gland is imaging using technetium (99mTc) scan [23]. In contrast, the treatment of secondary HPT revolves around controlling the underlying ESRD or vitamin D deficiency rather than removal of the parathyroid glands [24]. Medical management includes hemodialysis, low phosphate renal diet, treatment with calcimimetic drugs such as Cinacalcet, and vitamin D derivatives [1]. Renal transplantation, another option for patients with ESRD, can successfully reestablish normal kidney function [2]. Medical treatment has been shown to be sufficient in helping resolve these lesions, although the process is usually slow [2527]. Conversely, in cases of refractory disease, parathyroidectomy may still be required, in which case total parathyroidectomy is performed with removal of all four glands. Calcium supplementation for life is required in these patients [1, 5, 27].

Although removal of the parathyroid gland in HPT has been shown to lead to regression of the brown tumor and osseous remodeling, the patient’s age can be a factor in the rate of regression [16, 20]. When regression is slow, surgical removal of the tumor following parathyroidectomy has been shown to expedite the healing process [24, 28]. Some have also reported tumors failing to regress and continuing to grow even after HPT has been resolved, thus requiring surgical intervention [29, 30]. Others have reported success with the use of intralesional steroid therapy to promote tumor regression; in the same manner, this method has been used for central reparative giant cell granulomas [12, 31].

Table 1 summarizes the methods of treatment for the 87 cases of maxillofacial BTHPT identified in the last 10 years, where data was available. Over 50% of patients were treated with parathyroidectomy or medical management alone. The rest had a combination of treatment modalities, although the extent of surgical curettages and excisions were difficult to assess from reviewing these reports.

In our case, surgical excision was felt to be warranted due to the refractory nature of the secondary HPT and poor compliance with medical treatment. Furthermore, the tumor was large and compromised normal function and esthetics. Patients with ESRD can have recurrence of their tumors if the renal disease is not well controlled postoperatively [32]. Our patient is at risk of developing additional brown tumors due to his poor compliance with medical therapy and the lack of surgical follow-up. We do realize that this lack of surgical follow-up is a limitation of this case report.

4. Conclusion

Brown tumors are rare in developed countries, with only 5 cases reported in the United States over the last 10 years at the time of this writing. These occur more frequently in developing countries because they are usually the result of uncontrolled and untreated HPT, perhaps due to lack of access to care. Regression of BTHPT can often be achieved with medical therapy or performing parathyroidectomy in primary HPT, especially if the brown tumor is small. Larger lesions, such as the one described here, usually require some sort of surgical intervention. Additionally, microvascular reconstruction may not be possible in patients with ESRD with multiple comorbidities due to the risks associated with longer anesthesia.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Supplementary Materials

This video shows the surgical technique that was utilized for resection of this tumor. It also illustrates the size of the tumor and soft tissue involvement, necessitating a lip split mandibulotomy approach. Note that the tumor involves the mandibular ramus and encroaches on the condylar region as shown in the accompanying CT images.

  1. Supplementary Materials

References

  1. W. Saliba and B. El-Haddad, “Secondary hyperparathyroidism: pathophysiology and treatment,” Journal of the American Board of Family Medicine, vol. 22, no. 5, pp. 574–581, 2009. View at: Publisher Site | Google Scholar
  2. B. W. Neville, Oral and Maxillofacial Pathology, Saunders Elsevier, St. Louis, Mo, USA, 3rd edition, 2009.
  3. C. Pace and R. Crosher, “Simultaneously occurring brown tumours in the mandible and maxilla in a patient with vitamin D deficiency,” Australian Dental Journal, vol. 55, no. 4, pp. 453–456, 2010. View at: Publisher Site | Google Scholar
  4. J. S. Keyser and G. N. Postma, “Brown tumor of the mandible,” American Journal of Otolaryngology—Head and Neck Medicine and Surgery, vol. 17, no. 6, pp. 407–410, 1996. View at: Publisher Site | Google Scholar
  5. W. D. Fraser, “Hyperparathyroidism,” The Lancet, vol. 374, no. 9684, pp. 145–158, 2009. View at: Publisher Site | Google Scholar
  6. C. De Crea, E. Traini, L. Oragano, C. Bellantone, M. Raffaelli, and C. P. Lombardi, “Are brown tumours a forgotten disease in developed countries?” Acta Otorhinolaryngologica Italica, vol. 32, no. 6, pp. 410–415, 2012. View at: Google Scholar
  7. K. Triantafillidou, L. Zouloumis, G. Karakinaris, E. Kalimeras, and F. Iordanidis, “Brown tumors of the jaws associated with primary or secondary hyperparathyroidism. A clinical study and review of the literature,” The American Journal of Otolaryngology—Head and Neck Medicine and Surgery, vol. 27, no. 4, pp. 281–286, 2006. View at: Publisher Site | Google Scholar
  8. J. M. Jakubowski, I. Velez, and S. A. McClure, “Brown tumor as a result of hyperparathyroidism in an end-stage renal disease patient,” Case Reports in Radiology, vol. 2011, Article ID 415476, 3 pages, 2011. View at: Publisher Site | Google Scholar
  9. A. Oh, P. Mojica, M. Sullivan et al., “Malignant hypercalcemia associated with a parathyroid macrocyst and the early genesis of a giant cell tumor,” American Journal of Otolaryngology, vol. 27, no. 1, pp. 54–57, 2006. View at: Publisher Site | Google Scholar
  10. S. Rafizadeh, V. M. Duarte, C. Lai, and D. K. Chhetri, “Tumor of maxilla in a patient with hypercalcemia,” JAMA Otolaryngology—Head and Neck Surgery, vol. 139, no. 7, pp. 741–742, 2013. View at: Publisher Site | Google Scholar
  11. M. D. Walsh Jr., K. Chan, S. Travers, and R. C. McIntyre Jr., “Destructive maxillomandibular brown tumor in severe hyperparathyroidism,” Journal of the American College of Surgeons, vol. 201, no. 2, article 315, 2005. View at: Publisher Site | Google Scholar
  12. J. J. Wilson, H. C. Schwartz, and G. M. Tehrany, “Brown tumor of the posterior maxilla as initial manifestation of primary hyperparathyroidism: case report,” Journal of Oral and Maxillofacial Surgery, vol. 71, no. 5, pp. 886–890, 2013. View at: Publisher Site | Google Scholar
  13. F. S. Chew and F. Huang-Hellinger, “Brown tumor,” American Journal of Roentgenology, vol. 160, no. 4, article 752, 1993. View at: Publisher Site | Google Scholar
  14. J. A. Regezi, J. J. Sciubba, and R. C. K. Jordan, Oral Pathology: Clinical Pathologic Correlations, St. Louis, Mo, USA, Elsevier/Saunders, 6th edition, 2012.
  15. E. Proimos, T. S. Chimona, D. Tamiolakis, M. G. Tzanakakis, and C. E. Papadakis, “Brown tumor of the maxillary sinus in a patient with primary hyperparathyroidism: a case report,” Journal of Medical Case Reports, vol. 3, article 7495, 2009. View at: Publisher Site | Google Scholar
  16. J. S. M. Daniels, “Primary hyperparathyroidism presenting as a palatal brown tumor,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 98, no. 4, pp. 409–413, 2004. View at: Publisher Site | Google Scholar
  17. P. F. Pechalova and E. G. Poriazova, “Brown tumor at the jaw in patients with secondary hyperparathyroidism due to chronic renal failure,” Acta Medica, vol. 56, no. 2, pp. 83–86, 2013. View at: Google Scholar
  18. M. M. Suarez-Cunqueiro, R. Schoen, A. Kersten, J. Klisch, and R. Schmelzeisen, “Brown tumor of the mandible as first manifestation of atypical parathyroid adenoma,” Journal of Oral and Maxillofacial Surgery, vol. 62, no. 8, pp. 1024–1028, 2004. View at: Publisher Site | Google Scholar
  19. S. Gangidi, R. Dyer, and D. Cunliffe, “Not all radiolucencies of the jaw require enucleation: a case of brown tumour,” British Journal of Oral and Maxillofacial Surgery, vol. 50, no. 3, pp. e33–e35, 2012. View at: Publisher Site | Google Scholar
  20. J. A. Reséndiz-Colosia, S. A. Rodríguez-Cuevas, R. Flores-Díaz et al., “Evolution of maxillofacial brown tumors after parathyroidectomy in primary hyperparathyroidism,” Head and Neck, vol. 30, no. 11, pp. 1497–1504, 2008. View at: Publisher Site | Google Scholar
  21. N. Di Daniele, S. Condò, M. Ferrannini et al., “Brown tumour in a patient with secondary hyperparathyroidism resistant to medical therapy: case report on successful treatment after subtotal parathyroidectomy,” International Journal of Endocrinology, vol. 2009, Article ID 827652, 3 pages, 2009. View at: Publisher Site | Google Scholar
  22. M. C. Pinto, S. M. G. Sass, C. P. P. Sampaio, and D. S. Campos, “Brown tumor in a patient with hyperparathyroidism secondary to chronic renal failure,” Brazilian Journal of Otorhinolaryngology, vol. 76, no. 3, article 404, 2010. View at: Publisher Site | Google Scholar
  23. J. P. Bilezikian, M. L. Brandi, R. Eastell et al., “Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 10, pp. 3561–3569, 2014. View at: Publisher Site | Google Scholar
  24. C. T. S. Leal, P. G. S. Lacativa, E. M. S. Gomes et al., “Surgical approach and clinical outcome of a deforming brown tumor at the maxilla in a patient with secondary hyperparathyroidism due to chronic renal failure,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 50, no. 5, pp. 963–967, 2006. View at: Publisher Site | Google Scholar
  25. P. P. Nair, H. P. Gharote, S. Thomas, R. Guruprasad, and N. Singh, “Brown tumour of the jaw,” BMJ Case Reports, 2011. View at: Publisher Site | Google Scholar
  26. E. Fernández, M. Belart, and J. Montoliu, “Regression of a brown tumour after 3 years of treatment with intravenous calcitriol in a haemodialysis patient,” Nephrology Dialysis Transplantation, vol. 11, no. 2, pp. 398–399, 1996. View at: Publisher Site | Google Scholar
  27. F. O. Prado, A. C. D. M. N. Rosales, C. I. S. Rodrigues, R. D. Coletta, and M. A. Lopes, “Brown tumor of the mandible associated with secondary hyperparathyroidism: a case report and review of the literature,” General Dentistry, vol. 54, no. 5, pp. 341–343, 2006. View at: Google Scholar
  28. H. Yamazaki, Y. Ota, T. Aoki, and K. Karakida, “Brown tumor of the maxilla and mandible: progressive mandibular brown tumor after removal of parathyroid adenoma,” Journal of Oral and Maxillofacial Surgery, vol. 61, no. 6, pp. 719–722, 2003. View at: Publisher Site | Google Scholar
  29. R. R. Weiss, M. J. Schoeneman, W. Primack, D. Rozycki, B. Bennett, and I. Greifer, “Maxillary brown tumor of secondary hyperparathyroidism in a hemodialysis patient,” Journal of the American Medical Association, vol. 243, no. 19, pp. 1929–1930, 1980. View at: Publisher Site | Google Scholar
  30. I. Krause, B. Eisenstein, M. Davidovits, R. Cleper, A. Tobar, and S. Calderon, “Maxillomandibular brown tumor—a rare complication of chronic renal failure,” Pediatric Nephrology, vol. 14, no. 6, pp. 499–501, 2000. View at: Publisher Site | Google Scholar
  31. L. P. Pinto, K. Cherubinim, F. G. Salum, L. S. Yurgel, and M. A. Z. De Figueiredo, “Highly aggressive brown tumor in the jaw associated with tertiary hyperparathyroidism,” Pediatric Dentistry, vol. 28, no. 6, pp. 543–546, 2006. View at: Google Scholar
  32. A. P. Sumer, N. Arik, M. Sumer, and F. Karagoz, “A rare complication of secondary hyperparathyroidism. Brown tumor of the maxilla and mandible,” Saudi Medical Journal, vol. 25, no. 12, pp. 2010–2012, 2004. View at: Google Scholar
  33. S. Chowdhury, A. Aggarwal, N. Mittal, and A. Shah, “Brown tumor of hyperparathyroidism involving craniomaxillofacial region: a rare case report and literature review,” Minerva Stomatologica, vol. 62, no. 9, pp. 343–348, 2013. View at: Google Scholar
  34. W. Pawlak, A. Bohdanowicz-Pawlak, M. Bolanowski, J. Szymczak, G. Bednarek-Tupikowska, and K. Łuczak, “Primary hyperparathyroidism presenting as a giant cell tumor of the jaws,” Neuroendocrinology Letters, vol. 34, no. 2, pp. 107–110, 2013. View at: Google Scholar
  35. É. D. de Ávila, R. S. de Molon, M. A. C. Gabrielli et al., “Unusually rapid growth of brown tumour in the mandible after parathyroidectomy associated with the presence of a supernumerary parathyroid gland,” Journal of Cranio-Maxillofacial Surgery, vol. 40, no. 1, pp. e19–e23, 2012. View at: Publisher Site | Google Scholar
  36. P. V. Angadi, K. Rekha, and S. R. Shetty, “‘An exophytic mandibular brown tumor’: an unusual presentation of primary hyperparathyroidism,” Oral and Maxillofacial Surgery, vol. 14, no. 1, pp. 67–69, 2010. View at: Publisher Site | Google Scholar
  37. A. Benhammou, M. Meziane, N. Dib et al., “Maxilla-mandibular brown tumors as a first sign of parathyroid adenoma,” Annales d'Oto-Laryngologie et de Chirurgie Cervico-Faciale, vol. 126, no. 4, pp. 216–220, 2009. View at: Publisher Site | Google Scholar
  38. F. Selvi, S. Cakarer, R. Tanakol, S. D. Guler, and C. Keskin, “Brown tumour of the maxilla and mandible: a rare complication of tertiary hyperparathyroidism,” Dentomaxillofacial Radiology, vol. 38, no. 1, pp. 53–58, 2009. View at: Publisher Site | Google Scholar
  39. F. E. Karabekmez, A. Duymaz, M. Keskin, and Z. Tosun, “Huge deforming brown tumour at the maxilla and mandible in a patient with secondary hyperparathyroidism,” Journal of Plastic, Reconstructive and Aesthetic Surgery, vol. 61, no. 11, pp. 1404–1405, 2008. View at: Publisher Site | Google Scholar
  40. F. Tarrass, M. Benjelloun, and T. Bensaha, “Severe jaw enlargement associated with uremic hyperparathyroidism,” Hemodialysis International, vol. 12, no. 3, pp. 316–318, 2008. View at: Publisher Site | Google Scholar
  41. F. Jebasingh, J. J. Jacob, A. Shah, T. V. Paul, and M. S. Seshadri, “Bilateral maxillary brown tumours as the first presentation of primary hyperparathyroidism,” Oral and Maxillofacial Surgery, vol. 12, no. 2, pp. 97–100, 2008. View at: Publisher Site | Google Scholar
  42. A. D. Dinkar, S. Sahai, and M. Sharma, “Primary hyperparathyroidism presenting as an exophytic mandibular mass,” Dentomaxillofacial Radiology, vol. 36, no. 6, pp. 360–363, 2007. View at: Publisher Site | Google Scholar
  43. S. Desigan, R. Syed, G. S. Conway, T. R. Kurzawinski, and J. B. Bomanji, “Giant cervical parathyroid adenoma mimicking a sternocleidomastoid mass and presenting as a brown tumor of the mandible,” Clinical Nuclear Medicine, vol. 32, no. 4, pp. 306–308, 2007. View at: Publisher Site | Google Scholar
  44. V. Grulois, I. Buysschaert, J. Schoenaers, F. Debruyne, P. Delaere, and V. Vander Poorten, “Brown tumour: presenting symptom of primary hyperparathyroidism,” B-ENT, vol. 1, no. 4, pp. 191–195, 2005. View at: Google Scholar
  45. J. Fernández-Sanromán, I. M. Antón-Badiola, and A. Costas-López, “Brown tumor of the mandible as first manifestation of primary hyperparathyroidism: diagnosis and treatment,” Medicina Oral, Patologia Oral y Cirugia Bucal, vol. 10, no. 2, pp. 169–172, 2005. View at: Google Scholar
  46. N. Jović, R. Kozomara, S. Stosić, M. Broćić, R. Hrvacević, and S. Ilić, “Brown tumor of the maxilla in patient with secondary hyperparathyroidism,” Vojnosanitetski Pregled, vol. 61, no. 6, pp. 683–687, 2004. View at: Publisher Site | Google Scholar
  47. A. H. Emin, Y. Süoğlu, D. Demir, and M. C. Karatay, “Normocalcemic hyperparathyroidism presented with mandibular brown tumor: report of a case,” Auris Nasus Larynx, vol. 31, no. 3, pp. 299–304, 2004. View at: Publisher Site | Google Scholar
  48. I. G. Placed, B. Patiño-Seijas, J. Pombo-Otero, and R. Alvarez-Rodríguez, “Fine needle aspiration diagnosis of brown tumor of the maxilla,” Acta Cytologica, vol. 54, no. 5, supplement, pp. 1076–1078, 2010. View at: Google Scholar
  49. M. Pérez-Guillermo, J. Acosta-Ortega, J. García-Solano, and J. Ramos-Freixá, “Cytologic aspect of brown tumor of hyperparathyroidism. Report of a case affecting the hard palate,” Diagnostic Cytopathology, vol. 34, no. 4, pp. 291–294, 2006. View at: Publisher Site | Google Scholar
  50. A. H. Praveen and R. Thriveni, “Maxillary and mandibular hyperparathyroidism,” National Journal of Maxillofacial Surgery, vol. 3, no. 1, pp. 51–54, 2012. View at: Google Scholar
  51. K. V. Arunkumar, S. Kumar, and D. Deepa, “Brown tumor in mandible as a first sign of vitamin D deficiency: a rare case report and review,” Indian Journal of Endocrinology and Metabolism, vol. 16, no. 2, pp. 310–315, 2012. View at: Google Scholar
  52. N. Soundarya, P. Sharada, N. Prakash, and G. L. Pradeep, “Bilateral maxillary brown tumors in a patient with primary hyperparathyroidism: report of a rare entity and review of literature,” Journal of Oral and Maxillofacial Pathology, vol. 15, no. 1, pp. 56–59, 2011. View at: Publisher Site | Google Scholar
  53. Y. Sutbeyaz, O. Yoruk, H. Bilen, and N. Gursan, “Primary hyperparathyroidism presenting as a palatal and mandibular brown tumor,” The Journal of Craniofacial Surgery, vol. 20, no. 6, pp. 2101–2104, 2009. View at: Publisher Site | Google Scholar
  54. F. Mantar, S. Gunduz, and U. R. Gunduz, “A reference finding rarely seen in primary hyperparathyroidism: brown tumor,” Case Reports in Medicine, vol. 2012, Article ID 432676, 4 pages, 2012. View at: Publisher Site | Google Scholar
  55. Z. Nabi, M. Algailani, M. Abdelsalam, L. Asaad, and M. Albaqumi, “Regression of brown tumor of the maxilla in a patient with secondary hyperparathyroidism after a parathyroidectomy,” Hemodialysis International, vol. 14, no. 2, pp. 247–249, 2010. View at: Publisher Site | Google Scholar
  56. H.-K. Sia, M.-C. Hsieh, L.-H. Yang, and S.-T. Tu, “Maxillary brown tumor as initial presentation of parathyroid adenoma: a case report,” Kaohsiung Journal of Medical Sciences, vol. 28, no. 7, pp. 400–403, 2012. View at: Publisher Site | Google Scholar
  57. E. Bahrami, T. Alireza, H. Ebrahim, and S. Mohammadreza, “Maxillary and orbital brown tumor of primary hyperparathyroidism,” American Journal of Case Reports, vol. 13, pp. 183–186, 2012. View at: Publisher Site | Google Scholar
  58. V. Di Fede, O. Di Fede, V. Rodolico, G. Campisi, and A. Cordova, “Mandibular brown tumor as the first manifestation of primary hyperparathyroidism: a case report,” Annali di Stomatologia, vol. 4, supplement 2, pp. 14–15, 2013. View at: Google Scholar
  59. M. Alhusban and Z. H. Baqain, “Mandibular brown tumor as the first manifestation of primary hyperparathyroidism: a case report,” Saudi Dental Journal, vol. 23, no. 2, pp. 107–109, 2011. View at: Publisher Site | Google Scholar
  60. P. S. Pahlavan and M. C. Severin, “Parathyroid carcinoma: a rare case with mandibular brown tumor,” Wiener Klinische Wochenschrift, vol. 118, no. 5-6, pp. 175–179, 2006. View at: Publisher Site | Google Scholar
  61. C. Altay, N. Erdoğan, E. Eren, S. Altay, S. Karasu, and E. Uluç, “Computed tomography findings of an unusual maxillary sinus mass: brown tumor due to tertiary hyperparathyroidism,” Journal of Clinical Imaging Science, vol. 3, article 55, 2013. View at: Publisher Site | Google Scholar
  62. S. Artul, A. Bowirrat, M. Yassin, and Z. Armaly, “Maxillary and frontal bone simultaneously involved in brown tumor due to secondary hyperparathyroidism in a hemodialysis patient,” Case Reports in Oncological Medicine, vol. 2013, Article ID 909150, 4 pages, 2013. View at: Publisher Site | Google Scholar
  63. L.-A. Guldfred, S. Daugaard, and C. von Buchwald, “Brown tumor mimicking maxillary sinus mucocele as the first manifestation of primary hyperparathyroidism,” Auris Nasus Larynx, vol. 39, no. 4, pp. 418–421, 2012. View at: Publisher Site | Google Scholar
  64. D.-P. Magalhães, R.-L. Osterne, A.-P. Alves, P.-S. S. Santos, R.-B. Lima, and F.-B. Sousa, “Multiple brown tumours of tertiary hyperparathyroidism in a renal transplant recipient: a case report,” Medicina Oral, Patologia Oral y Cirugia Bucal, vol. 15, no. 1, pp. e10–e13, 2010. View at: Publisher Site | Google Scholar
  65. A. R. Pati, Mubeen, K. R. Vijayalakshmi, and C. Singh, “Diagnosis and clinico-radiological presentation in an aggressive maxillary brown tumour,” Journal of Clinical and Diagnostic Research, vol. 8, no. 5, pp. ZD13–ZD15, 2014. View at: Publisher Site | Google Scholar
  66. H. Mori, Y. Okada, T. Arao, S. Shimaziri, and Y. Tanaka, “A case of multiple brown tumors with primary hyperparathyroidism,” Journal of Bone and Mineral Metabolism, vol. 31, no. 1, pp. 123–127, 2013. View at: Publisher Site | Google Scholar
  67. M. Benjelloun, F. Tarrass, L. Alaoui et al., “Marked facial enlargement in secondary hyperparathyroidism,” Nephrology Dialysis Transplantation, vol. 22, no. 10, pp. 3082–3083, 2007. View at: Publisher Site | Google Scholar
  68. S. Thomas, P. Nair, K. Hegde, and S. Neelakantan, “A bilaterally recurring exophytic mass on the lower jaw,” BMJ Case Reports, vol. 2011, 2011. View at: Publisher Site | Google Scholar
  69. A. Guerrouani, A. Rzin, and K. El Khatib, “Hyperparathyroidism-jaw tumour syndrome detected by aggressive generalized osteitis fibrosa cystica,” Clinical Cases in Mineral and Bone Metabolism, vol. 10, no. 1, pp. 65–67, 2013. View at: Google Scholar

Copyright © 2015 Mohammed Qaisi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1448 Views | 823 Downloads | 10 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.